NH SPAC 2 (KQ:206640) — Market Cap & Net Worth
Market Cap & Net Worth: NH SPAC 2 (206640)
NH SPAC 2 (KQ:206640) has a market capitalization of $169.86 Million (₩250.65 Billion) as of May 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #17145 globally and #772 in its home market, demonstrating a -1.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NH SPAC 2's stock price ₩11690.00 by its total outstanding shares 21441206 (21.44 Million). Analyse 206640 cash flow conversion to see how efficiently the company converts income to cash.
NH SPAC 2 Market Cap History: 2015 to 2026
NH SPAC 2's market capitalization history from 2015 to 2026. Data shows change from $457.14 Million to $169.86 Million (-6.95% CAGR).
Index Memberships
NH SPAC 2 is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$299.07 Billion | 0.06% | #302 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$299.07 Billion | 0.06% | #302 of 1384 |
Weight: NH SPAC 2's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
NH SPAC 2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NH SPAC 2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
NH SPAC 2's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
NH SPAC 2's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $457.14 Million | $39.82 Billion | -$1.97 Billion | 0.01x | N/A |
| 2016 | $256.07 Million | $54.97 Billion | $12.62 Billion | 0.00x | 0.02x |
| 2017 | $244.85 Million | $52.59 Billion | -$2.15 Billion | 0.00x | N/A |
| 2018 | $147.05 Million | $66.20 Billion | -$1.69 Billion | 0.00x | N/A |
| 2019 | $133.31 Million | $72.80 Billion | $11.65 Billion | 0.00x | 0.01x |
| 2020 | $330.39 Million | $144.13 Billion | $45.49 Billion | 0.00x | 0.01x |
| 2021 | $237.15 Million | $157.71 Billion | $44.37 Billion | 0.00x | 0.01x |
| 2022 | $146.83 Million | $118.08 Billion | $24.15 Billion | 0.00x | 0.01x |
| 2023 | $293.65 Million | $134.22 Billion | $25.95 Billion | 0.00x | 0.01x |
| 2024 | $243.82 Million | $138.16 Billion | $27.26 Billion | 0.00x | 0.01x |
Competitor Companies of 206640 by Market Capitalization
Companies near NH SPAC 2 in the global market cap rankings as of May 4, 2026.
Key companies related to NH SPAC 2 by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
NH SPAC 2 Historical Marketcap From 2015 to 2026
Between 2015 and today, NH SPAC 2's market cap moved from $457.14 Million to $ 169.86 Million, with a yearly change of -6.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩169.86 Million | -10.90% |
| 2025 | ₩190.64 Million | -21.81% |
| 2024 | ₩243.82 Million | -16.97% |
| 2023 | ₩293.65 Million | +100.00% |
| 2022 | ₩146.83 Million | -38.09% |
| 2021 | ₩237.15 Million | -28.22% |
| 2020 | ₩330.39 Million | +147.84% |
| 2019 | ₩133.31 Million | -9.34% |
| 2018 | ₩147.05 Million | -39.94% |
| 2017 | ₩244.85 Million | -4.38% |
| 2016 | ₩256.07 Million | -43.98% |
| 2015 | ₩457.14 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of NH SPAC 2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $169.86 Million USD |
| MoneyControl | $169.86 Million USD |
| MarketWatch | $169.86 Million USD |
| marketcap.company | $169.86 Million USD |
| Reuters | $169.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NH SPAC 2
Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testi… Read more